Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by Schulhoff & Co. Inc.

Schulhoff & Co. Inc. increased its stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 190.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 122,000 shares of the company’s stock after buying an additional 80,000 shares during the quarter. Schulhoff & Co. Inc. owned about 0.21% of Pyxis Oncology worth $448,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Bank of New York Mellon Corp boosted its holdings in Pyxis Oncology by 92.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock worth $1,031,000 after acquiring an additional 149,522 shares during the period. abrdn plc lifted its position in shares of Pyxis Oncology by 28.9% during the third quarter. abrdn plc now owns 913,045 shares of the company’s stock worth $3,351,000 after purchasing an additional 204,742 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after purchasing an additional 743,499 shares during the period. Blue Owl Capital Holdings LP acquired a new stake in Pyxis Oncology during the 2nd quarter valued at $3,462,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Pyxis Oncology during the 1st quarter worth $351,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Trading Down 7.4 %

Shares of PYXS opened at $4.28 on Thursday. Pyxis Oncology, Inc. has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a market cap of $254.32 million, a price-to-earnings ratio of -4.16 and a beta of 1.27. The stock has a 50 day moving average of $3.66 and a 200-day moving average of $3.66.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. On average, sell-side analysts predict that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PYXS has been the subject of several recent analyst reports. Stephens assumed coverage on Pyxis Oncology in a research note on Friday, November 8th. They set an “overweight” rating and a $13.00 target price for the company. Stifel Nicolaus initiated coverage on Pyxis Oncology in a report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, September 19th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, August 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $9.57.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.